AGILENT TECHNOLOGIES, INC. (A)

Agilent Technologies Inc., incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application-focused solutions including instruments, software, services and consumables for the entire laboratory workflow. As of fiscal year ended October 31, 2022, the company employed approximately 18,100 people worldwide and operates through three business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment (approximately 6,900 employees, 53,800 customers) offers instruments, software and consumables spanning liquid and gas chromatography, mass spectrometry, spectroscopy, cell analysis, lab automation, vacuum technologies and remarketed instruments, serving pharmaceutical/biopharma/CRO/CMO, academic and government, chemicals and advanced materials, environmental and forensics, and food markets; key competitors include Danaher, PerkinElmer, Shimadzu, Thermo Fisher Scientific and Waters.

The Diagnostics and Genomics segment (approximately 3,200 employees, 11,900 customers) encompasses genomics, nucleic acid contract manufacturing (producing oligonucleotide APIs under GMP conditions), pathology (cancer diagnostics and anatomic pathology, including IHC, ISH, and staining products), companion diagnostics developed in partnership with pharmaceutical companies, reagent partnerships supplying flow cytometry reagents and antibodies, and biomolecular analysis for nucleic acid quality control; this segment is subject to FDA and other regulatory oversight, and competitors include Abbott, Illumina, Leica Biosystems (Danaher), Roche Ventana, Avecia (Nitto Denko) and Twist Bioscience. The Agilent CrossLab segment (approximately 5,300 employees, 49,200 customers) provides a largely vendor-neutral services portfolio spanning startup, operational, training, compliance, asset management and consultative services across the same end markets, plus the diagnostics and clinical market, with recurring revenue that is less susceptible to seasonality than the instrument businesses. The company sells primarily through direct sales, supplemented by distributors, resellers, manufacturers' representatives and e-commerce, and conducts centralized manufacturing and supply chain operations across sites in the U.S. (California, Colorado, Delaware, Massachusetts, Texas, Vermont, Washington, Iowa) and internationally (Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the UK).

As of April 30, 2022, the aggregate market value of common equity held by non-affiliates was approximately $26.6 billion, and as of December 9, 2022, there were 296,072,040 shares of common stock outstanding, par value $0.01 per share.